Table 1.
Patients characteristics.
| Total | TPX | SPX | LPX | p value | |
|---|---|---|---|---|---|
| No. of patients | 33 | 17 | 4 | 12 | |
| Age (y) |
43 (43.4 ± 14.1) |
47 (48.0 ± 16.49) |
41 (42.0 ± 10.8) |
36 (37.4 ± 8.9) |
0.135 |
| Follow-up period (m) |
58 (65.2 ± 42.5) |
42 (47.4 ± 19.8) |
127 (109.0 ± 70.1) |
83 (76.0 ± 45.0) |
0.130 |
|
Preoperative Ca (mg/dL) |
10.7 (10.7 ± 0.7) |
10.9 (10.7 ± 0.8) |
10.7 (11.1 ± 0.8) |
10.6 (10.6 ± 0.6) |
0.522 |
|
Preoperative iPTH (pg/mL) |
147.1 (154.6 ± 79.8) |
154.5 (190.9 ± 90.6) |
140.1 (138.1 ± 52.2) |
104.1 (108.8 ± 37.7) |
0.017* |
| Genetically confirmed | 31 (93.9%) | 17 (100%) | 3 (75%) | 11 (91.7%) | 0.227 |
| Other MEN1 Sx | 28 (84.8%) | 16 (94.1%) | 4 (100%) | 8 (66.7%) | 0.131 |
|
No. preoperative -detected parathyroid |
2.0 (1.9) | 2.0 (2.1 ± 0.7) | 3.0 (2.8 ± 0.5) | 1.0 (1.4 ± 0.5) | 0.001* |
| No. intraoperative-confirmed abnormal parathyroid | 3.0 (3.0) | 4.0 (4.1 ± 0.9) | 3.3 (3.3 ± 0.3) | 1.5 (1.5 ± 0.5) | 0.000* |
| No. pathologically confirmed adenoma/hyperplasia | 4.0 (3.0) | 4.0 | 3.0 (2.8 ± 1.3) | 1.0 (1.4 ± 0.5) | 0.000* |
| Auto-transplantation | 17 (51.5%) | 17 (100%) | 0 (0) | 0 (0) | 0.000* |
| Thymectomy | 11 (33.3%) | 10 (58.8%) | 0 (0) | 1 (9.1%) | 0.004* |
Data are presented as median or mean ± SD, *p < 0.05.
TPX total parathyroidectomy, SPX subtotal parathyroidectomy, LPX less-than-subtotal parathyroidectomy.
Other MEN1 Sx includes pancreatic neuroendocrine tumour and pituitary adenoma.